SCHEMBL7970119

SCHEMBL7970119

CCOc1nc(N2CCCCC2)c2nc(OCC)nc(N3CCCCC3)c2n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC29A1 Q99808 12/20 0.66
▸ ALDH1A1 P00352 7/20 0.51
▸ TSHR P16473 4/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ LMNA P02545 3/20 0.51
▸ GAA P10253 2/20 0.51
▸ TDP1 Q9NUW8 2/20 0.51
▸ GALR3 O60755 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ MAPK1 P28482 1/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ NPSR1 Q6W5P4 3/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ CYP3A4 P08684 2/20 0.41
▸ CYP2C9 P11712 2/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ PDE2A O00408 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7976583 0.86 SLC29A1 (0.71) SLC29A1ALDH1A1TSHRSMN1; SMN2LMNA
SCHEMBL7971739 0.81 SLC29A1 (0.60) SLC29A1ALDH1A1TSHRSMN1; SMN2LMNA
SCHEMBL7971382 0.79 HTT (0.60) SLC29A1ALDH1A1TSHRSMN1; SMN2LMNA
SCHEMBL7960351 0.79 SLC29A1 (0.61) SLC29A1ALDH1A1TSHRSMN1; SMN2LMNA
SCHEMBL7976494 0.78 MAPT (0.64) SLC29A1ALDH1A1TSHRSMN1; SMN2LMNA
SCHEMBL1276832 0.76 SLC29A1 (0.61) SLC29A1ALDH1A1TSHRSMN1; SMN2LMNA
SCHEMBL7973587 0.75 SLC29A1 (0.53) SLC29A1ALDH1A1TSHRSMN1; SMN2LMNA
SCHEMBL7949410 0.75 SLC29A1 (0.63) SLC29A1ALDH1A1TSHRSMN1; SMN2LMNA
SCHEMBL7947717 0.73 SLC29A1 (0.86) SLC29A1ALDH1A1TSHRSMN1; SMN2LMNA
SCHEMBL7948817 0.73 SLC29A1 (0.57) SLC29A1ALDH1A1TSHRSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240166770-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES YALE UNIVERSITY 2024-05-23 — — US disclosed
WO-2021077070-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES YALE UNIVERSITY (US) 2021-04-22 — — WO disclosed
US-6297250-B1 USEFUL FOR INHIBITING TRANSPORT OF NUCLEOSIDES OR PURINES ACROSS CELL MEMBRANES, THEREBY TO POTENTIATE THE ACTIVITY OF VARIOUS CYTOTOXIC ANTITUMOR DRUGS NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) 2001-10-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166770-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES SLC29A1, SLC29A2, SLC7A1 SLC29A1 1/4885ALDH1A1 2004/4885TSHR 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback